Notice of Intent to Publish a Funding Opportunity Announcement for Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)
ID: 356540Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Viral INfections in the Young Lung (VINYL) Clinical Consortium, aimed at supporting research on severe viral lower respiratory tract infections (LRTI) in children aged 0-2 years. This initiative will involve the establishment of a consortium to phenotype affected children and follow them until preschool age to assess pulmonary sequelae, utilizing a phased award structure to fund various centers, including a Data and Analytics Coordinating Center and multiple Clinical Centers. The total funding available is projected to be up to $31.6 million, with the NOFO expected to be published in February 2025 and applications due by June 2025, leading to funding decisions anticipated in February 2026. Interested applicants should prepare their proposals in advance of these deadlines.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Human Virome Program, which aims to develop innovative tools and methods for characterizing the human virome and understanding its impact on health and disease. This initiative seeks to address technological challenges in identifying and analyzing human-associated viruses, inviting applicants to propose projects that enhance the study of the human virome through novel tools and bioinformatics methods. The program is significant for advancing knowledge that could lead to new health-related biomarkers and therapeutic strategies, with NIH planning to commit approximately $2.5 million to fund 4-5 awards, each with a maximum budget of $350,000 per year for up to four years. Applications are due by January 27, 2025, with the earliest project start date anticipated for July 2025; for further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the NHLBI SBIR Phase IIB Small Market Awards aimed at accelerating the commercialization of technologies for heart, lung, blood, and sleep disorders. This funding opportunity is designed to support small businesses in advancing promising biomedical projects that have previously received SBIR or STTR Phase II funding, specifically targeting products that address rare diseases or pediatric populations. With an estimated total program funding of $21 million and an award ceiling of $3.5 million, the anticipated application due date is February 25, 2025, with awards expected to be made by December 1, 2025. Interested applicants are encouraged to prepare their proposals in advance to meet the requirements integral to this initiative.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science, inviting R01 research applications that focus on biomedical and behavioral research to inform tobacco product regulation. This initiative aims to generate scientific data that will enhance public health protections related to tobacco use, with a particular emphasis on fostering diverse perspectives through a simplified peer review framework. The total estimated funding for this program is $4 million, with an award ceiling of $500,000 for each of the anticipated five awards, and the NOFO is expected to be published in Winter 2024, with applications due in Summer 2025. Interested applicants should prepare to submit new applications, as only new proposals will be considered, and further details will be available upon the official release of the NOFO.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at enhancing the understanding of the neurological effects associated with infection-related chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This initiative encourages research projects that explore the neurological and psychiatric manifestations of these illnesses, with a particular interest in studies that may identify common neuropsychiatric mechanisms across multiple conditions, although applications focusing on individual illnesses are also welcome. The NOFO is anticipated to be released in Fall 2024, with applications due in Winter 2025, and will utilize the R21 grant mechanism. Interested applicants should prepare for a project start date expected in December 2025, with further details to be outlined in the forthcoming announcement.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at accelerating substance use research through the utilization of existing data, specifically under the R21 grant mechanism. This initiative seeks to foster innovative research projects that leverage pre-existing datasets to enhance understanding and treatment of substance use disorders. The total estimated funding for this program is $2 million, with an award ceiling of $200,000 per project and an anticipated three awards to be made. Interested applicants should note that the NOFO is expected to be published in Fall 2024, with applications due in Spring 2025, and the estimated award date is set for April 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.